Success Metrics

Clinical Success Rate

66.7%

Based on 2 completed trials

Completion Rate

67%(2/3)

Active Trials

0(0%)

Results Posted

100%(2 trials)

Terminated

1(33%)

Phase Distribution

Ph not_applicable

33%

Ph phase_2

33%

Ph phase_3

33%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution3 total trials

Phase 2Efficacy & side effects

1(33.3%)

Phase 3Large-scale testing

1(33.3%)

N/ANon-phased studies

1(33.3%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

66.7%

2 of 3 finished

Non-Completion Rate

33.3%

1 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Completed(2)

Terminated(1)

Detailed Status

Completed2

Terminated1

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

66.7%

Most Advanced

Phase 3

Trials by Phase

Phase 21 (33.3%)

Phase 31 (33.3%)

N/A1 (33.3%)

Trials by Status

completed267%

terminated133%

Recent Activity

0 active trials

Showing 3 of 3

completednot_applicable

Silver Diamine Fluoride Pilot Study (SDF)

NCT02591147

terminatedphase_2

PATCH 2&3:Prevention & Treatment of COVID-19 (Severe Acute Respiratory Syndrome Coronavirus 2) With Hydroxychloroquine

NCT04353037

completedphase_3

An Efficacy Study for Epoetin Alfa in Anemic Patients With Myelodysplastic Syndromes

NCT01381809

Clinical Trials (3)

Showing 3 of 3 trials

NCT02591147Not Applicable

Silver Diamine Fluoride Pilot Study (SDF)

Completed

NCT04353037Phase 2

PATCH 2&3:Prevention & Treatment of COVID-19 (Severe Acute Respiratory Syndrome Coronavirus 2) With Hydroxychloroquine

Terminated

NCT01381809Phase 3

An Efficacy Study for Epoetin Alfa in Anemic Patients With Myelodysplastic Syndromes

Completed

All 3 trials loaded

Drug Details

Intervention Type: DRUG
Total Trials: 3